Thermo Fisher Scientific Basiliximab Chimeric Recombinant Mouse Monoclonal Antibody (Basiliximab)

Applications and Tested Dilution

Product Specifications

Product Specific Information

Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit. Binding is abolished when two or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc). T cells express CD25 only upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.

Target Information

Basiliximab is a recombinant chimeric (murine/human) monoclonal antibody (IgG1κ) that functions as an immunosuppressive agent. It specifically binds to and blocks the interleukin-2 receptor α-chain (IL-2Rα, also known as CD25 antigen) on the surface of activated T-lymphocytes.
It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to IL-2Rα.
Basiliximab binds with high affinity to the α-subunit (CD25) of the high-affinity IL-2 receptor, inhibiting IL-2 binding and T-cell activation, thereby preventing immune response against foreign kidney tissue.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.